Brief: Silence Therapeutics Announces Positive Topline 48-Week Data From Phase 2 Study Of Zerlasiran In Patients With Elevated Lipoprotein
20/06/2024 13:21
June 20 (Reuters) - Silence Therapeutics PLC SLNCF.PK :
* SILENCE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE 48-WEEK
DATA
FROM PHASE 2 STUDY OF ZERLASIRAN IN PATIENTS WITH ELEVATED
LIPOPROTEIN(A)
* SILENCE THERAPEUTICS: STUDY DEMONSTRATED HIGHLY
SIGNIFICANT AND
SUSTAINED REDUCTIONS IN LP(A) TO WEEK 48
Source text for Eikon: ID:nBwfCPg0a
Further company coverage: SLNCF.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silence Therapeutics
See all newsBrief: Silence Therapeutics Reports Second Quarter 2025 Financial Results And Recent Business Highlights
Brief: Silence Therapeutics files for stock shelf, size not disclosed
Brief: Silence Therapeutics Announces Positive Results From Ongoing Sanreco Phase 1 Study
Brief: Silence Therapeutics Announces Positive Topline 48-Week Data From Phase 2 Study Of Zerlasiran In Patients With Elevated Lipoprotein
Brief: Silence Therapeutics PLC Files For Resale Of Up To 5.71 Million Shares By The Selling Securityholders - SEC Filing